

## Cross-Sectional Study

### Effect of Insulin Resistance on Left Ventricular Remodeling in Essential Hypertensives: A Cross Sectional Study

Kianu Phanzu Bernard<sup>1,2\*</sup>, Nkondila Natuhoyila Aliocha<sup>3</sup>, Kintoki Vita Eleuthère<sup>1</sup>, Longo-Mbenza Benjamin<sup>1</sup> and M'Buyamba Kabangu Jean-René<sup>1</sup>

<sup>1</sup>Cardiology Unit, Department of internal Medicine, University of Kinshasa Hospital, Kinshasa, DR Congo

<sup>2</sup>Centre Médical de Kinshasa (CMK), Kinshasa, DR Congo

<sup>3</sup>School of Public Health, Department of Biostatistics, Kinshasa, DR Congo

#### Abstract

**Background:** In clinical practice, left ventricular hypertrophy is defined not by the left ventricular walls thickness, but by the left ventricular mass. The later is calculated according to the Devereux's formula, and is increased by insulin resistance/hyperinsulinemia. It is however unclear which of insulin resistance, hyperinsulinemia, or both is actually causative and what is their collective or individual influence on the components of Devereux's formula and parameters of left ventricular diastolic function. The present study evaluated the associations of the Homeostatic Model Assessment for Insulin Resistance (HOMAIR) and fasting plasma insulin with components of Devereux's formula and parameters of left ventricular diastolic function.

**Methods:** Relevant clinical data were collected from 220 hypertensive patients recruited between January and December 2019. The associations of components of Devereux's formula and parameters of diastolic function with insulin resistance were tested using binary ordinal, conditional and classical logistic regression models.

**Results:** Thirty-two (14.5%) patients (43.9 ± 9.1 years), 99 (45%) patients (52.4 ± 8.7 years), and 89 (40.5%) patients (53.1 ±

9.8 years) had normal left ventricular geometry, concentric left ventricular remodeling and concentric left ventricular hypertrophy respectively. In multivariable adjusted analysis 46.8% of variation in interventricular septum diameter ( $R^2 = 0.468$ ; overall  $p < 0.001$ ), and 30.9% in E-wave deceleration time ( $R^2 = 0.309$ ; overall  $p = 0.003$ ) were explained by insulin and HOMAIR, 30.1% of variation in left ventricular end-diastolic diameter ( $R^2 = 0.301$ ;  $p = 0.013$ ) by HOMAIR alone and 46.3% of posterior wall thickness ( $R^2 = 0.463$ ;  $p = 0.002$ ) and 29.4% of relative wall thickness ( $R^2 = 0.294$ ;  $p = 0.007$ ) by insulin alone.

**Conclusion:** Insulin resistance and hyperinsulinemia do not have the same influence on the components of Devereux's formula. Insulin resistance appears to act on the left ventricular end diastole diameter, while hyperinsulinemia affects the posterior wall thickness. Both abnormalities act on the interventricular septum and contribute to diastolic dysfunction via the E wave deceleration time.

**Keywords:** Diastolic dysfunction; Hyperinsulinemia; Hypertension; Insulin resistance; Left ventricular remodeling

#### Background

Hypertensive patients with Insulin Resistance (IR) are at increased cardiovascular risk compared to hypertensive patients without IR [1]. Likewise, the presence of Target Organ Damage (TOD) Including Left Ventricular Hypertrophy (LVH), is associated with poor prognosis in hypertensive patients [2]. International guidelines therefore recommend considering hypertensive patients with target organ damage, including LVH, as being at high cardiovascular risk [3-5].

Hypertension-induced LVH is a known corollary not only of barometric overload secondary to high blood pressure, but also of various metabolic abnormalities induced by IR [6,7] and hyperinsulinemia [8,9].

LVH represents a phenotype of the formidable capacity of the heart to adapt to various constraints, in order to maintain a cardiac output sufficient to meet the metabolic needs of the whole organism. This left ventricular remodeling is defined as the set of changes in the size, shape and function of the left ventricle [10].

Left ventricular hypertrophy has a poor prognosis [2,10-12]. It is defined not by the ventricular walls thickness, but by the Left Ventricular Mass (LVM) calculated according to the formula of Devereux as  $LVM (g) = 0.8 (1.04 [(LVED+IVS+PWT)^3 - LVED^3]) + 0.6 g$  [13], where LVED indicates left ventricular end-diastolic diameter, IVS indicates interventricular septal thickness, and PWT indicates posterior wall thickness. Thus any factor that increases LVM, might affect at least one among the following components: left ventricular end-diastolic diameter and/or the thickness of the left interventricular septum, and / or the thickness of the posterior wall (LVED, and/or IVS, and / or PWT). Because IR and hyperinsulinemia do increase LVM, the purpose of this study was to assess the collective and isolated influence of IR/hyperinsulinemia on each component of the Devereux formula and on diastolic function parameters.

\*Corresponding author: Kianu Phanzu Bernard, Division of Cardiology, Department of Internal Medicine, University of Kinshasa Hospital, Kinshasa, DR Congo, Tel: +243 997 622 019; E-mail: doctorkianu@gmail.com

Citation: Bernard KP, Aliocha NN, Eleuthère KV, Benjamin LM, Jean-René MBK (2021) Effect of Insulin Resistance on Left Ventricular Remodeling in Essential Hypertensives: A Cross Sectional Study. J Cardiol Stud Res 6: 018.

Received: February 03, 2021; Accepted: March 26, 2021; Published: April 02, 2021

Copyright: © 2021 Bernard KP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## Methods

### Study design and setting

This was a cross sectional study conducted in Centre Médical de Kinshasa (CMK) between January and December 2019. The CMK is a reference clinic with a cardiology center named, Pôle de Cardiologie, where cardiovascular exploration such as doppler echocardiography, coronary scanner and a cardiopulmonary exercise testing are performed. It operates with highly qualified personnel, regularly retrained.

### Participants selection

Two hundred and twenty hypertensive asymptomatic patients (133 men, 60.4%) aged  $51.5 \pm 9.7$  years, were consecutively enrolled during outpatient consultations at the Pôle de Cardiologie of the Center Médical de Kinshasa (CMK), between January and December 2019. The inclusion criteria were age of 20 years and above and absence of clinical or laboratory evidence of secondary hypertension, renal or hepatic disease. Patients with heart disease unrelated to high blood pressure were excluded from participation.

### Study procedures

**Anamnestic data:** Demographic data (age, sex), lifestyle habits (heavy alcohol consumption, current smoking, sedentary behavior), medical history including cardiovascular risk factors (age at diagnosis of high blood pressure, history of diabetes mellitus, dyslipidemia, hyperuricemia, menopause) and previous cardiovascular events (stroke, ischemic heart disease, heart failure, Chronic Kidney Disease, cardiovascular surgery), and current medication use for chronic disease (antihypertensive treatment, anti-diabetic treatment and other treatments including statins, antiplatelet agents, hypouricemics, oral contraception, hormone replacement therapy) were collected during an in-person directed interview using ad hoc questionnaire.

**Anthropometric data:** Anthropometric parameters measured by a trained observer consisted in measurements of body weight, height, waist and hip circumference according to WHO recommendations. Body weight was measured in kilograms using a validated electronic balance on a stable and flat surface, with participant in light clothing and shoes. The reading was made to the nearest 100 g. Height was measured with a measuring rod, to the nearest centimeter, with participant standing barefoot and bareheaded. Waist circumference was measured to the nearest 0.1 cm, using a measuring tape applied directly to the skin along the horizontal line passing through the umbilicus. The Body Surface Area (BSA) was calculated using the Dubois formula as follows:  $BSA = \text{Height} \times 0.725 \times \text{Weight} \times 0.425 \times 0.007184$  [14]. BMI was obtained by dividing the weight (Kg) by the height (m) squared.

### Blood pressure

BP was measured non-invasively by 24 Hour-Ambulatory Blood Pressure Monitoring (ABPM) using a TONOPORT V (GE Health care, Freiburg, GERMANY) type recorder. During this recording, the participant was asked to maintain his usual way of life.

### Echocardiographic data

Left ventricular measurements were obtained according to the updated 2015 American Society of Echocardiography and European

Association of Cardiovascular Imaging guidelines for cardiac chamber quantification using a Vivid T8 (GE) type ultrasound system equipped with 3.5 MHz transducers [15]. Two-dimensionally guided M-mode echocardiography was performed on a parasternal long-axis view. Interventricular Septum Thickness (IVS), Left Ventricular End-Diastolic Diameter (LVED), and Posterior Wall Thickness (PWT), were measured at end-diastole at a level just below the mitral valve leaflets. Simultaneous ECG was used to correlate measurements with the cardiac cycle. Diastolic wall thickness was measured at the onset of the QRS wave. LVM was calculated according to the American Society of Echocardiography simplified cubed equation linear method using the following equation:  $LVM \text{ (grams)} = 0.8 \times 1.04 \times [(LVED + IVS + PWT)^3 - (LVED)^3] + 0.6 \text{ g}$ . LVM was indexed by BSA and by height<sup>2.7</sup>. The Relative Wall Thickness (RWT) of the Left Ventricle (LV) was calculated as  $(2 \times PWT) / LVED$ .

In accordance with international recommendations [16], the parameters of LV diastolic function were measured by recording transmitral flow velocity using conventional doppler echocardiography with pulsed wave Doppler (PW), transmitral flow velocity was recorded from the apical transducer position with the sample volume situated between the mitral leaflet tips. E (Peak E-wave velocity), A (Peak A-wave velocity) and Deceleration Time of early filling (DT), were recorded in apical four-chamber with color flow imaging for optimal alignment of PW Doppler with blood flow. PW Doppler sample volume (1-3 mm axial size) was placed between mitral leaflet tips using low wall filter setting (100-200 MHz) and low signal gain, so that the optimal spectral waveforms would not display spikes. E, A and DT were measured as the averages of five consecutive cardiac cycles. The E/A ratio was calculated. Tissue Doppler echocardiography, which measures the velocity of the regional cardiac wall, was performed by activating the tissue doppler echocardiographic function, as for two dimensional and M-mode echocardiography as for two dimensional and M-mode echocardiography. Mitral annular velocities were recorded from the apical window. Sample volumes were located at the lateral site of the mitral annulus. Peak early diastolic mitral annular velocity (E', cm/s) was measured over five cardiac cycles and the mean calculated. The ratio E/e' was used as a parameter of left atrial pressure, which is elevated with progression of LV diastolic dysfunction. These parameters, obtained by tissue doppler echocardiography, were also used as parameters of LV diastolic function.

### Laboratory Parameters

For all analyzes, a blood sample was taken between 7 a.m. and 9 a.m. from the cubital vein of the patient fasting since 10 p.m. of the previous day. All analyzes were carried out at the CMK laboratory. For the determination of serum uric acid, total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides, blood was collected in a dry tube and the assay performed by colorimetric spectrophotometer (HELIOS Epsilon, Milwaukee, USA). The blood glucose test was performed on plasma oxalate by colorimetric method using standard reagents (Biolabo) and measured by the HELIOS Epsilon spectrophotometer. The dosage of insulin was performed on EDTA plasma by ELISA. Reading the optical density was done on a string read from the firm HUMAREADER HUMAN (Germany).

## Operational Definitions

- Hyperinsulinemia was defined as fasting insulin > 90 mmol / L.
- Insulin resistance was defined by a HOMAIR  $\geq 2.5$  [17]
- Normal LVM was defined as  $\leq 115 \text{ g/m}^2$  or  $\leq 48 \text{ g/m}^{2.7}$  in males and  $\leq 95 \text{ g/m}^2$  or  $\leq 44 \text{ g/m}^{2.7}$  in females, with LVH defined as LVM exceeding those values [18]
- Four LV geometric patterns were defined as follows [18,19]: normal geometry (normal LVM and  $\text{RWT} \leq 0.42$ ); concentric remodeling (normal LVM and  $\text{RWT} > 0.42$ ); concentric hypertrophy (LVH and  $\text{RWT} > 0.42$ ); and eccentric hypertrophy (LVH and  $\text{RWT} \leq 0.42$ ).
- Three patterns of Diastolic Dysfunction (DD) was defined as follow [20,21]: abnormal relaxation (grade I: E/A ratio <1 and prolonged deceleration time) ; pseudo-normal relaxation (grade II: E/A ratio >1 and intermediate values of deceleration time) ; and restrictive patterns (reversible and irreversible, grade III–IV respectively; E/A ratio > 2 and shortened deceleration time).
- The dilation of the left atrium was defined by Left Atrium Area (LAA) >20 cm<sup>2</sup> of body surface [15].

## Statistical analysis

Data are presented as Number (n) and relative frequencies (%) for categorical variables and average ( $\pm$  standard deviation) for quantitative variables. Paired comparisons were carried out by Pearson Chi-square or Fischer's Exact test as appropriate for categorical variables and multiple comparison of continuous variables (means and medians) by ANOVA and H test of Kruskal Wallis. ANOVA tests found to be significant at the threshold of  $p < 0.05$  were supplemented by a post hoc test by Scheffé. The influence of HOMAIR and insulinemia on the left ventricular and diastolic parameters was investigated by linear regression in simple exploratory analysis respectively. Correlation coefficients (r) were calculated to determine the degree of association between left ventricular and diastolic parameters, and HOMAIR on the one hand and insulinemia on the other. When differences were observed between the ultrasound parameters and HOMAIR or insulin, the effect of potential confounders was studied by adjustment in multiple linear regression. Finally, the determination coefficients (R<sup>2</sup>), were calculated to determine the degree of association between the ultrasound parameters of the left ventricle and HOMAIR or insulin. The significance threshold was  $p < 0.05$ . Statistical analyzes were performed using XLStat 2020 (Oxford, UK) and SPSS (Statistic Package for Social Sciences) 20 for Windows version 24 software (Chicago, USA).

## Ethical considerations

This research was conducted in strict compliance with the recommendations of the Helsinki Declaration III. Approval to conduct the study was obtained from the ethics committee of the University of Kinshasa Public Health School prior to its commencement. Each participant provided written informed consent to participate in the study. All respondents were debriefed on the results of the study.

## Results

Socio-demographic and clinical characteristics of the patients according to left ventricular geometry are shown in Table 1. Thirty-two (14.5%) patients ( $43.9 \pm 9.1$  years), 99 (45%) patients

( $52.4 \pm 8.7$  years), and 89 (40.5%) patients ( $53.1 \pm 9.8$  years) had normal left ventricular geometry, concentric left ventricular remodeling and concentric left ventricular hypertrophy respectively. No cases of eccentric left ventricular hypertrophy were found. Patients with left ventricular hypertrophy were significantly older than patients with normal left ventricular geometry and more often had a history of hypertension, with higher 24-hour mean systolic blood pressure, while patients with normal ventricular geometry were more often newly diagnosed with hypertension. Patients with LVH were more often sedentary, obese, hyperuricemic, and insulin resistant, and more often with dyslipidemia and high atherogenicity index.

Variables	All n=220	Normal VG n=32	Concentric Remodeling n=99	Concen- tric LVH n=89	p
Age, Years	51.5 $\pm$ 9.7	43.9 $\pm$ 9.1	52.4 $\pm$ 8.7	53.1 $\pm$ 9.8	<0.001
Sex, n (%)					0.802
Male	133(60.5)	18(56.3)	62(62.6)	53(59.6)	
Female	87(39.5)	14(43.8)	37(37.4)	36(40.4)	
T2DM	26(11.8)	4(12.5)	13(13.1)	9(10.1)	0.811
Known HTN	136(61.8)	12(37.5)	63(63.6)	61(68.5)	0.007
ND HTN	84(38.2)	20(62.5)	36(36.4)	28(31.5)	0.009
Overweight	86(39.1)	15(46.9)	49(49.5)	22(24.7)	0.001
Obesity	112(50.9)	10(31.3)	36(36.4)	66(74.2)	<0.001
Abdominal Obesity	97(44.1)	5(15.6)	37(37.4)	55(61.8)	<0.001
Sedentary	123(55.9)	6(18.8)	45(45.5)	72(80.9)	<0.001
Dyslipidemia	173(78.6)	18(56.3)	79(79.8)	76(85.4)	<0.005
High AI					
93(42.3)	8(25.0)	39(39.4)	46(51.7)	0.023	
Hyperuricemia	51(23.2)	3(9.4)	19(19.2)	29(32.6)	0.011
Uncontrolled HTN	182(82.7)	28(87.5)	85(85.9)	69(77.5)	0.250
BMI (Kg/cm <sup>2</sup> )	30.2 $\pm$ 5.0	28.2 $\pm$ 4.8	28.7 $\pm$ 4.0	32.6 $\pm$ 5.1	0.000
SBP (mmHg)	135.9 $\pm$ 7.9	132.2 $\pm$ 7.9	133.8 $\pm$ 6.9	138.9 $\pm$ 7.8	0.000
DBP (mmHg)	81.0 $\pm$ 9.0	79.8 $\pm$ 7.5	79.9 $\pm$ 9.7	82.5 $\pm$ 8.6	0.143
WC (cm)	103.3 $\pm$ 12.4	95.4 $\pm$ 9.8	100.4 $\pm$ 9.8	109.4 $\pm$ 13.1	0.000
HR (bpm)	67.9 $\pm$ 13.7	69.1 $\pm$ 17.2	70.5 $\pm$ 11.5	62.1 $\pm$ 13.5	0.437
Hyperinsulinemia	19(8.6)	2(6.3)	8(8.1)	9(10.1)	0.848
Insulin resistance	44(20.0)	1(3.1)	0(0.0)	43(48.3)	<0.001

**Table 1:** Sociodemographic and clinical characteristics of patients according to left ventricular geometry.

T2D = Type 2 Diabetes Mellitus; HTN = Hypertension; ND HTN = Newly-Diagnosed Hypertension; AI = Atherogenic Index; BMI = Body Mass Index; SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure

The biological and echographic characteristics are shown in table 2. The mean values of glycaemia, total cholesterol, LDL-C, triglyceride, atherogenicity index, HbA1c, uricemia, insulinemia, HOMAIR, mitral E wave deceleration time, left atrium area, and systolic Pulmonary Artery Pressure (sPAP) were significantly higher in patients with LVH compared to those with normal left ventricular geometry, whereas E/A ratio was lower.

As illustrated in table 3, the correlation between HOMAIR and LVED, IVS, PWT, SWT, LVMih, LVMibsa, RWT and E wave deceleration was 29.8%, 41.6%, 42.6%, 44.1%, 43.7%, 44.5%, 23.9%, and 24.9%, respectively.

Variables	Total N=220	Normal n=32	Concentric Remodeling n=99	Concentric LVH n=89	p
Glycemia (mmol/L)	5.8±1.9	5.2±1.2	5.4±1.6	6.4±2.2	<0.001
TC (mmol/L)	5.5±1.0	5.0±1.0	5.5±1.0	5.5±1.0	0.027
LDL-C (mmol/L)	3.7±1.1	3.3±1.1	3.7±1.1	3.9±1.1	0.047
Triglycerides (mmol/L)	1.14±0.6	0.91±0.4	1.11±0.6	1.25±0.6	0.029
HDL-C (mmol/L)	1.21±0.3	1.27±0.3	1.28±0.4	1.13±0.3	0.009
AI	4.8±1.6	4.1±0.9	4.7±1.9	5.2±1.6	0.005
HbA1C (%)	6.1±1.3	5.7±1.0	5.9±1.0	6.4±1.6	0.016
Creatinine (mmol/L)	84.5±19.0	84.5±18.1	84.3±15.8	84.6±22.5	0.991
Uric Acid (mmol/L)	367.1±94.6	317.1±78.6	363.6±90.7	388.2±97.9	0.001
Insulin (mmol/L)	92.9±41.8	68.2±21.4	73.3±25.8	123.2±43.0	<0.001
Calcium (mmol/L)	2.33±0.2	2.32±0.3	2.34±0.2	2.30±0.2	0.269
Ionized Calcium (mmol/L)	1.21±0.2	1.24±0.2	1.21±0.1	1.20±0.1	0.380
Phosphorus (mmol/L)	1.08±0.2	1.14±0.5	1.08±0.2	1.06±0.2	0.270
Hb (mg/dl)	13.4±1.4	13.6±1.6	13.4±1.4	13.3±1.3	0.595
HOMAIR	1.79±0.8	1.42±0.8	1.39±0.5	2.37±0.8	<0.001
LVED (mm)	44.3±4.6	45.7±2.6	41.9±4.0	46.5±4.4	<0.001
IVS (mm)	11.5±1.7	9.0±1.2	11.2±1.3	12.7±1.1	<0.001
PWT (mm)	11.4±1.6	9.0±0.8	11.2±1.3	12.5±0.9	<0.001
SWT	22.9±3.1	18.1±1.9	22.3±2.4	25.2±1.6	<0.001
LVEF	64.6±5.1	63.8±4.4	65.5±4.9	63.7±5.4	0.038
LVM (g)	183.0±48.4	139.5±24.6	160.9±34.3	222.8±38.5	<0.001
LVMlh (g/m <sup>2.7</sup> )	44.4±11.1	34.4±5.2	38.4±6.4	54.7±8.4	<0.001
LVMlbsa (g/m <sup>2</sup> )	91.2±20.8	71.9±10.5	81.8±15.1	108.6±15.6	<0.001
RWT	0.52±0.1	0.40±0.1	0.54±0.1	0.55±0.07	<0.001
E (Cm/s)	0.99±0.7	1.31±0.9	1.00±0.5	0.86±0.9	0.015
E/A ratio	0.99±0.2	1.15±0.1	0.75±0.2	0.71±0.2	0.010
DT (ms)	201.9±40.0	178.1±29.4	197.8±39.2	215.3±39.6	<0.001
Sa (cms)	12.4±1.4	12.9±1.2	12.3±1.2	12.4±1.6	0.096
LAA (cm <sup>2</sup> )	15.7±3.3	13.8±1.9	14.9±2.8	17.3±3.5	<0.001
sPAP (mmHg)	26.4±2.9	24.5±1.9	26.5±2.7	27.0±3.1	<0.001

**Table 2:** Biological and ultrasound characteristics of patients according to left ventricular geometry.

Variables are presented as mean ± SD or n (%).

TC = Total Cholesterol; LDLc = Low-Density Lipoprotein; HDLc = High-Density Lipoprotein; AI = Atherogenic Index; HbA1C = Glycated Haemoglobin; Hb = Haemoglobin; HOMAIR = Homeostatic Model Assessment for Insulin Resistance; LVED = Left Ventricular End-Diastolic; IVS = Interventricular Septum Diameter; PWT = Posterior Wall Thickness; SWT = Sum of Wall Thickness; LVEF = Left Ventricular Ejection Fraction; LVM = Left Ventricular Mass; LVMlh = Left Ventricular Mass Indexed to height<sup>2.7</sup>; LVMlbsa = Left Ventricular Mass Indexed to body surface area; RWT = Relative Wall Thickness; E = Peak E-wave velocity; DT = Deceleration Time; LAA = Left Atrial Area; sPAP = systolic Pulmonary Arterial Pressure.

Multiple linear regression (Table 4) demonstrated that insulin and HOMAIR explained 46.8% of the increase in IVS ( $R^2 = 0.468$ ) and 30.9% of the increase in DT ( $R^2 = 0.309$ ). HOMAIR alone explained 30.1% of the increase in LVED ( $R^2 = 0.301$ ). Insulin alone explained 46.3% of the increase in PWT ( $R^2 = 0.463$ ) and 29.4% for RWT ( $R^2 = 0.294$ ).

Variables	HOMAIR		Insulin	
	r	p	R	p
LVED (mm)	0.298	<0.001	0.273	<0.001
IVS (mm)	0.416	<0.001	0.468	<0.001
PWT (mm)	0.426	<0.001	0.463	<0.001
SWT	0.441	<0.001	0.489	<0.001
LVMlh (g/m <sup>2.7</sup> )	0.437	<0.001	0.448	<0.001
LVMlbsa (g/m <sup>2</sup> )	0.445	<0.001	0.472	<0.001
RWT	0.239	<0.001	0.288	<0.001
DT (ms)	0.249	<0.001	0.304	<0.001

**Table 3:** Correlation between HOMAIR, insulinemia and left ventricular mensurations and diastolic function parameters.

LVED = Left Ventricular End-Diastole Diameter; IVS = Interventricular Septum; PWT = Posterior Wall Thickness; SWT = Sum Of Wall Thickness; LVMlh = Left Ventricular Mass Indexed to height<sup>2.7</sup>; LVMlbsa = Left Ventricular Mass indexed to body surface area; RWT = Relative Wall Thickness; DT = Deceleration Time.

Parameters	Equation parameters				
	β	SE	P	R2	Overall p
LVED (mm)				0.301	0.001
(constant)	41.375	0.729	0.000		
HOMAIR	1.599	0.823	0.013		
Insulin	0.001	0.017	0.954		
IVS (mm)				0.468	<0.001
(constant)	9.723	0.254	0.000		
HOMAIR	0.860	0.287	0.016		
Insulin	0.021	0.006	0.000		
PWT (mm)				0.463	<0.001
(constant)	9.787	0.230	0.000		
HOMAIR	0.063	0.260	0.810		
Insulin	0.016	0.005	<b>0.002</b>		
RWT				0.294	<b>0.011</b>
(constant)	0.467	0.014	<b>0.000</b>		
HOMAIR	0.014	0.016	0.377		
Insulin	0.001	0.000	<b>0.007</b>		
DT ms				0.309	0.003
(constant)	175.610	6.374	<b>0.000</b>		
HOMAIR	6.453	7.203	<b>0.017</b>		
Insulin	0.409	0.145	<b>0.005</b>		

**Table 4:** Multiple linear regression analysis between HOMAIR, Insulin and LV echographic parameters.

LVED = Left Ventricular End-Diastole Diameter; IVS = Interventricular Septum; PWT = Posterior Wall Thickness; RWT = Relative Wall Thickness; DT = Deceleration Time

## Discussion

The purpose of the present study was to evaluate the associations of insulin resistance/hyperinsulinemia with components of Devereux's formula and parameters of left ventricular diastolic function.

The results suggest that insulin resistance and hyperinsulinemia have different effects on components of Devereux's formula depending on whether they act in synergy or in isolation. Insulin

resistance alone appears to increase LVM only by dilation of LVED while hyperinsulinemia alone may increase LVM by a trophic effect on the posterior wall. Only their synergistic action seems to have a trophic effect on the IVS but also a deleterious effect on diastolic function.

The pathophysiological mechanisms by which IR promotes LVH and diastolic dysfunction have been the subject of several experimental studies [22-24]. The starting point of a complex metabolic cascade during IR, culminating in structural and functional anomalies of the left ventricle, is the almost exclusive recourse to the metabolism of fatty acids as fuel. Indeed, in a situation of adequate insulin sensitivity, free fatty acids constitute the main fuel for the production of energy necessary for uninterrupted and highly endergonic myocardial activity [22,25]. However, the heart machinery is capable of remarkable metabolic adaptability, allowing it, if necessary, to resort to other sources of energy such as glucose, pyruvate and ketone bodies [22,26].

On the contrary, in the IR state, this metabolic flexibility is lost [27]. The synthesis of glycogen and the catabolism of proteins in skeletal muscles is impaired, and the activity of lipoprotein lipases in adipocytes is inhibited, resulting in an increased release of free fatty acids and inflammatory cytokines such as IL-6, TNF $\alpha$  and leptin [28,29]. The heart is therefore integrated in an environment rich in fatty acids and glucose [30-33]. This stimulates the absorption of free fatty acids into the myocardium [33,34] due to upregulation of CD36 [31], which is a powerful transporter of free fatty acids, thus increasing the levels of intracellular fatty acids and the expression of PPAR- $\alpha$ . The excess lipids in the cardiomyocytes are transferred into non-oxidative pathways, leading to the accumulation of toxic lipid species such as ceramides, diacylglycerols, long chain acyl-CoA and acylcarnitines [35], which contribute to alteration of mitochondrial function, apoptosis, and cardiac hypertrophy [36,37].

Insulin regulates a wide range of functions in the heart, including heart growth [38]. The responsibility for hyperinsulinemia, which may be a cause or a consequence of insulin resistance in the development of left ventricular hypertrophy and the deterioration of diastolic function [8,9,39-41], is generally accepted and could be explained accounted for by trophic and profibrotic properties of insulin [8,9,42,43].

The dilator effect of insulin resistance on the LVED could be explained by volume overload. The latter is the consequence of the insulin induced sodium retention [44-47].

Our results indicate that 29.4% of variation in RWT could be explained by insulinemia suggesting a concentric remodeling. We also found that IR and hyperinsulinemia do increase the DT which is a parameter of a grade I diastolic dysfunction in 31% ( $R^2 = 0.309$ ) [19,21]. These findings are in accordance with the results of a population-based prospective study by Cauwenberghs, et al. [48], showing that basal insulin resistance and its increase during follow-up, was positively associated with development of concentric LVH. Similarly, Velagaleti et al. assessed the influence of IR on LVM measured by MRI, and also concluded that IR caused concentric LVH [49]. Participants in Cauwenberghs et al. study, who remained or became insulin resistant during follow-up experienced worse changes in  $E/e'$ , which is a parameter of DD [19,21]. Such a diastolic dysfunction is probably imputable to IR with underlying left ventricular hypertrophy and myocardial fibrosis [21,50-54]. But this

is, however, still a subject of debate as a certain degree of diastolic dysfunction exists in hypertensive patients long before they develop LVH [55], and as LVH regression of after antihypertensive treatment does not necessarily lead to normalization of diastolic function [56]. Nonetheless, some studies have shown that normalization of the left ventricular mass leads to normalization of diastolic function [57].

Therefore, IR/hyperinsulinemia appears to increase cardiovascular risk in patients with hypertension, at least in part, by promoting concentric LVH and diastolic dysfunction. Indeed, concentric LVH is the independent cardiovascular risk factor most strongly associated with a poor prognosis and diastolic dysfunction is a strong predictor of cardiovascular outcomes in essential hypertension [12,58,59].

Our study has to be interpreted within the context of its potential strengths and limitations. To the best of our knowledge, this is the first study to address the question of the collective or individual influence of insulin resistance / hyperinsulinemia on the components of Devereux's formula and on the parameters of diastolic function in the Africans. However echocardiographic measurements are prone to errors as a result of signal noise, acoustic artefacts, and angle dependency although in the present study, echocardiography was performed by an experienced cardiologist with post-graduate training in cardiac imaging. Moreover, the cross-sectional design of this study is a limitation, which means that causal relationships cannot be firmly established. Finally, the in-hospital and single-center design precludes extrapolation of the results to all essential hypertensive patients.

## Conclusion

Our study suggests that insulin resistance appears to act on left ventricular end diastole diameter, while hyperinsulinemia affects the posterior wall thickness. Both conditions do act on the interventricular septum and contribute to diastolic dysfunction via the E wave deceleration time. Insulin sensitivity of hypertensive patients should therefore be of concern to the physician managing hypertension, in order to take appropriate measures to improve prognosis. A prospective population-based study with serial imaging remains essential to better understand subclinical LV deterioration over time and to confirm the role of insulin resistance in essential hypertensives.

## Authors Contribution

Design and concept of study: KPB.

Acquisition of data: KPB.

Manuscript draft: KPB.

Supervision: KVE, LMB, MJR.

Statistical analysis: NNA.

All authors read and approved the final manuscript.

## Acknowledgement

We gratefully acknowledge Dr Rodolph Amhed, Managing Director of the Centre Médical de Kinshasa for granting us permission to conduct this study in CMK.

## References

1. Bigazzi R, Bianchi S, Buoncrisiani E, Campese VM (2008) Increased cardiovascular events in hypertensive patients with insulin resistance: A 13-year follow-up. *Nutr Metab Cardiovasc Dis* 18: 314-319.

2. Brescane RC (2009) The prognostic significance of left ventricular geometry: Fantasy or reality? *Rev Esp Cardiol* 62: 235-238.
3. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, et al. (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J* 39: 3021-3104.
4. Bakris G, Ali W, Parati G (2019) ACC/AHA Versus ESC/ESH on Hypertension Guidelines: JACC Guideline Comparison. *J Am Coll Cardiol* 73: 3018-3026.
5. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, et al. (2017) ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension* 71: 13-115.
6. Ilercic A, Devereux RB, Roman MJ, Paranicas M, O'grady MJ, et al. (2001) Relationship of impaired glucose tolerance to left ventricular structure and function: The Strong Heart Study. *Am Heart J* 141: 992-998.
7. Devereux RB, Roman MJ, Paranicas M, O'grady MJ, Lee ET, et al. (2000) Impact of diabetes on cardiac structure and function: the strong heart study. *Circulation* 101: 2271-2276.
8. Cardona-Munoz EG, Cardona-Müller D, Totsuka-Sutto S, Nuño-Guzmán CM, Pascoe-González S, et al. (2007) Association of hyperinsulinemia with left ventricular hypertrophy and diastolic dysfunction in patients with hypertension. *Rev Med Chil* 135: 1125-1131.
9. Yu W, Chen C, Fu Y, Wang X, Wang W (2010) Insulin signaling: a possible pathogenesis of cardiac hypertrophy. *Cardiovasc Ther* 28: 101-105.
10. Cohn JN, Ferrari R, Sharpe N (2000) Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. *J Am Coll Cardiol* 35: 569-582.
11. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. *N Engl J Med* 322: 1561-1566.
12. de Simone G (2004) Concentric or eccentric hypertrophy: How clinically relevant is the difference? *Hypertension* 43: 714-715.
13. Devereux RB, Reichek N (1977) Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. *Circulation* 55: 613-618.
14. Du Bois D, Bois EFD (1989) A formula to estimate the approximate surface area if height and weight be known. 1916. *Nutrition* 5: 303-311.
15. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, et al. (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* 16: 233-270.
16. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, et al. (2016) Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 29: 277-314.
17. Kim SH, Moon JY, Lim YM, Kim KH, Yang WI, et al. (2015) Association of insulin resistance and coronary artery remodeling: an intravascular ultrasound study. *Cardiovasc Diabetol* 14: 74-80.
18. Oktay AA, Lavie CJ, Milani RV, Ventura HO, Gilliland YE, et al. (2016) Current Perspectives on Left Ventricular Geometry in Systemic Hypertension. *Prog Cardiovasc Dis* 59: 235-246.
19. Silbiger JJ (2019) Pathophysiology and Echocardiographic Diagnosis of Left Ventricular Diastolic Dysfunction. *J Am Soc Echocardiogr* 32: 216-232.
20. Galderisi M, Cosyns B, Edvardsen T, Cardim N, Delgado V, et al. (2017) Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* 18: 1301-1310.
21. Nagueh SF (2020) Left Ventricular Diastolic Function: Understanding Pathophysiology, Diagnosis, and Prognosis with Echocardiography. *JACC Cardiovasc Imaging* 13: 228-44.
22. Witteles RM, Fowler MB (2008) Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. *J Am Coll Cardiol* 51: 93-102.
23. Velez M, Kohli S, Sabbah HN (2014) Animal models of insulin resistance and heart failure. *Heart Fail Rev* 19: 1-13.
24. Ouwens DM, Boer C, Fodor M, Diamant M, Massen JA, et al. (2005) Cardiac dysfunction induced by high-fat diet is associated with altered myocardial insulin signalling in rats. *Diabetologia* 48: 1229-1237.
25. Kota SK, Kota SK, Jammula S, Panda S, Modi KD (2011) Effect of diabetes on alteration of metabolism in cardiac myocytes: Therapeutic implications. *Diabetes Technol Ther* 13: 1155-1160.
26. Goodwin GW, Taegtmeier H (2000) Improved energy homeostasis of the heart in the metabolic state of exercise. *Am J Physiol Heart Circ Physiol* 279: 1490-1501.
27. Oakes ND, Thalen P, Aasum E, Edgley A, Larsen T et al. (2006) Cardiac metabolism in mice: tracer method developments and *in vivo* application revealing profound metabolic inflexibility in diabetes. *Am J Physiol Endocrinol Metab* 290: 870-881.
28. Wilcox G (2005) Insulin and insulin resistance. *Clin Biochem Rev* 26: 19-39.
29. Reaven GM (1995) Pathophysiology of insulin resistance in human disease. *Physiol Rev* 75: 473-86.
30. Malfitano C, Junior ALS, Carbonaro M, Bolsoni-Lopes A, Figueroa D, et al. (2015) Glucose and fatty acid metabolism in infarcted heart from streptozotocin-induced diabetic rats after 2 weeks of tissue remodeling. *Cardiovasc Diabetol* 14: 149.
31. Su X, Abumrad NA (2009) Cellular fatty acid uptake: a pathway under construction. *Trends Endocrinol Metab* 20: 72-7.
32. Kolwicz SC Jr, Purohit S, Tian R (2013) Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. *Circ Res* 113: 603-616.
33. Wright JJ, Kim J, Buchanan J, Boudina S, Sena S, et al. (2009) Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. *Cardiovasc Res* 82: 351-60.
34. Carley AN, Severson DL (2005) Fatty acid metabolism is enhanced in type 2 diabetic hearts. *Biochim Biophys Acta* 1734: 112-26.
35. D'Souza K, Nzirorera C, Kienesberger PC (2016) Lipid metabolism and signaling in cardioclipotoxicity. *Biochim Biophys Acta* 1861: 1513-24.
36. Goldberg IJ, Trent CM, Schulze PC (2012) Lipid metabolism and toxicity in the heart. *Cell Metab* 15: 805-812.
37. Unger RH, Orci L (2002) Lipoapoptosis: its mechanism and its diseases. *Biochim Biophys Acta* 1585: 202-212.
38. Fu Q, Wang Q, Xiang YK (2017) Insulin and beta Adrenergic Receptor Signaling: Crosstalk in Heart. *Trends Endocrinol Metab* 28: 416-427.
39. Shanik MH, Xu Y, Skrha J, Danker R, Zick Y et al. (2008) Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? *Diabetes Care* 2: 262-268.

40. Jia G, Whaley-Connell A, Sowers JR (2018) Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. *Diabetologia* 61: 21-28.
41. Jia G, DeMarco VG, Sowers JR (2016) Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. *Nat Rev Endocrinol* 12: 144-153.
42. Yasuoka H, Garrett SM, Nguyen X-X, Artlett CM, Feghali-Bostwick CA (2019) NADPH oxidase-mediated induction of reactive oxygen species and extracellular matrix deposition by insulin-like growth factor binding protein-5. *Am J Physiol Lung Cell Mol Physiol* 316: 644-655.
43. Gore-Hyer E, Pannu J, Smith EA, Grotendorst G, Trojanowska M (2003) Jaspreet Pannu, Edwin A Smith, Gary Grotendorst, Maria Trojanowska. *Arthritis Rheum* 48: 798-806.
44. Sarafidis PA, Bakris GL (2007) The antinatriuretic effect of insulin: an unappreciated mechanism for hypertension associated with insulin resistance? *Am J Nephrol* 27: 44-54.
45. Yatabe MS, Yatabe J, Yoneda M, Watanabe T, Otsuki M, et al. (2010) Salt sensitivity is associated with insulin resistance, sympathetic overactivity, and decreased suppression of circulating renin activity in lean patients with essential hypertension. *Am J Clin Nutr* 92: 77-82.
46. Nosadini R, Sambataro M, Thomaseth K, Pacini G, Cipollina MR, et al. (1993) Role of hyperglycemia and insulin resistance in determining sodium retention in non-insulin-dependent diabetes. *Kidney Int* 44: 139-1346.
47. Zhou MS, Wang A, Yu H (2014) Link between insulin resistance and hypertension: What is the evidence from evolutionary biology? *Diabetol Metab Syndr* 6: 12-19.
48. Cauwenberghs N, Knez J, Thijs L, Haddad F, Vanassche T, et al. (2018) Relation of Insulin Resistance to Longitudinal Changes in Left Ventricular Structure and Function in a General Population. *J Am Heart Assoc* 7: 008315.
49. Velagaleti RS, Gona P, Chuang ML, Salton CJ, Fox CS, et al. (2010) Relations of insulin resistance and glycemic abnormalities to cardiovascular magnetic resonance measures of cardiac structure and function: the Framingham Heart Study. *Circ Cardiovasc Imaging* 3: 257-263.
50. Devereux RB, de Simone G, Palmieri V, Oberman A, Hopkins P, et al. (2002) Relation of insulin to left ventricular geometry and function in African American and white hypertensive adults: the HyperGEN study. *Am J Hypertens* 15: 1029-1035.
51. Lopez BA, Gonzalez A, Diez J (2010) Circulating Biomarkers of Collagen Metabolism in Cardiac Diseases. *Circulation* 121: 1645-1654.
52. Ihm SH, Youn H-J, Shin D-I, Jang S-W, Park C-S, et al. (2007) Serum carboxy-terminal propeptide of type I procollagen (PIP) is a marker of diastolic dysfunction in patients with early type 2 diabetes mellitus. *Int J Cardiol* 122: 36-38.
53. Wachtell K, Smith G, Gerds G, Dahlöf B, Nieminen MS, et al. (2000) Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). *Losartan Intervention For Endpoint*. *Am J Cardiol* 85: 466-472.
54. Spinale FG (2002) Bioactive peptide signaling within the myocardial interstitium and the matrix metalloproteinases. *Circ Res* 91: 1082-1084.
55. Laviades C, Mayor G, Diez J (1991) The presence of diastolic dysfunction in hypertensive patients without left ventricular hypertrophy. *Med Clin (Barc)* 97: 166-169.
56. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, et al. (2009) Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy. *Circulation* 119: 530-537.
57. Wachtell K, Bella JN, Rokkedal J, Palmieri V, Papademetriou V, et al. (2002) Change in Diastolic Left Ventricular Filling After One Year of Antihypertensive Treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. *Circulation* 105: 1071-1076.
58. Palmiero P, Zito A, Maiello M, Cameli M (2015) Left Ventricular Diastolic Function in Hypertension: Methodological Considerations and Clinical Implications *J Clin Med Res* 7: 137-144.
59. Schillaci G, Pasqualini L, Verdecchia P, Vaudo G, Marchesi S, et al. (2002) Prognostic Significance of Left Ventricular Diastolic Dysfunction in Essential Hypertension. *J Am Coll Cardiol* 39: 2005-2011.



Advances In Industrial Biotechnology | ISSN: 2639-5665  
Advances In Microbiology Research | ISSN: 2689-694X  
Archives Of Surgery And Surgical Education | ISSN: 2689-3126  
Archives Of Urology  
Archives Of Zoological Studies | ISSN: 2640-7779  
Current Trends Medical And Biological Engineering  
International Journal Of Case Reports And Therapeutic Studies | ISSN: 2689-310X  
Journal Of Addiction & Addictive Disorders | ISSN: 2578-7276  
Journal Of Agronomy & Agricultural Science | ISSN: 2689-8292  
Journal Of AIDS Clinical Research & STDs | ISSN: 2572-7370  
Journal Of Alcoholism Drug Abuse & Substance Dependence | ISSN: 2572-9594  
Journal Of Allergy Disorders & Therapy | ISSN: 2470-749X  
Journal Of Alternative Complementary & Integrative Medicine | ISSN: 2470-7562  
Journal Of Alzheimers & Neurodegenerative Diseases | ISSN: 2572-9608  
Journal Of Anesthesia & Clinical Care | ISSN: 2378-8879  
Journal Of Angiology & Vascular Surgery | ISSN: 2572-7397  
Journal Of Animal Research & Veterinary Science | ISSN: 2639-3751  
Journal Of Aquaculture & Fisheries | ISSN: 2576-5523  
Journal Of Atmospheric & Earth Sciences | ISSN: 2689-8780  
Journal Of Biotech Research & Biochemistry  
Journal Of Brain & Neuroscience Research  
Journal Of Cancer Biology & Treatment | ISSN: 2470-7546  
Journal Of Cardiology Study & Research | ISSN: 2640-768X  
Journal Of Cell Biology & Cell Metabolism | ISSN: 2381-1943  
Journal Of Clinical Dermatology & Therapy | ISSN: 2378-8771  
Journal Of Clinical Immunology & Immunotherapy | ISSN: 2378-8844  
Journal Of Clinical Studies & Medical Case Reports | ISSN: 2378-8801  
Journal Of Community Medicine & Public Health Care | ISSN: 2381-1978  
Journal Of Cytology & Tissue Biology | ISSN: 2378-9107  
Journal Of Dairy Research & Technology | ISSN: 2688-9315  
Journal Of Dentistry Oral Health & Cosmesis | ISSN: 2473-6783  
Journal Of Diabetes & Metabolic Disorders | ISSN: 2381-201X  
Journal Of Emergency Medicine Trauma & Surgical Care | ISSN: 2378-8798  
Journal Of Environmental Science Current Research | ISSN: 2643-5020  
Journal Of Food Science & Nutrition | ISSN: 2470-1076  
Journal Of Forensic Legal & Investigative Sciences | ISSN: 2473-733X  
Journal Of Gastroenterology & Hepatology Research | ISSN: 2574-2566  
Journal Of Genetics & Genomic Sciences | ISSN: 2574-2485  
Journal Of Gerontology & Geriatric Medicine | ISSN: 2381-8662  
Journal Of Hematology Blood Transfusion & Disorders | ISSN: 2572-2999  
Journal Of Hospice & Palliative Medical Care  
Journal Of Human Endocrinology | ISSN: 2572-9640  
Journal Of Infectious & Non Infectious Diseases | ISSN: 2381-8654  
Journal Of Internal Medicine & Primary Healthcare | ISSN: 2574-2493  
Journal Of Light & Laser Current Trends  
Journal Of Medicine Study & Research | ISSN: 2639-5657  
Journal Of Modern Chemical Sciences  
Journal Of Nanotechnology Nanomedicine & Nanobiotechnology | ISSN: 2381-2044  
Journal Of Neonatology & Clinical Pediatrics | ISSN: 2378-878X  
Journal Of Nephrology & Renal Therapy | ISSN: 2473-7313  
Journal Of Non Invasive Vascular Investigation | ISSN: 2572-7400  
Journal Of Nuclear Medicine Radiology & Radiation Therapy | ISSN: 2572-7419  
Journal Of Obesity & Weight Loss | ISSN: 2473-7372  
Journal Of Ophthalmology & Clinical Research | ISSN: 2378-8887  
Journal Of Orthopedic Research & Physiotherapy | ISSN: 2381-2052  
Journal Of Otolaryngology Head & Neck Surgery | ISSN: 2573-010X  
Journal Of Pathology Clinical & Medical Research  
Journal Of Pharmacology Pharmaceutics & Pharmacovigilance | ISSN: 2639-5649  
Journal Of Physical Medicine Rehabilitation & Disabilities | ISSN: 2381-8670  
Journal Of Plant Science Current Research | ISSN: 2639-3743  
Journal Of Practical & Professional Nursing | ISSN: 2639-5681  
Journal Of Protein Research & Bioinformatics  
Journal Of Psychiatry Depression & Anxiety | ISSN: 2573-0150  
Journal Of Pulmonary Medicine & Respiratory Research | ISSN: 2573-0177  
Journal Of Reproductive Medicine Gynaecology & Obstetrics | ISSN: 2574-2574  
Journal Of Stem Cells Research Development & Therapy | ISSN: 2381-2060  
Journal Of Surgery Current Trends & Innovations | ISSN: 2578-7284  
Journal Of Toxicology Current Research | ISSN: 2639-3735  
Journal Of Translational Science And Research  
Journal Of Vaccines Research & Vaccination | ISSN: 2573-0193  
Journal Of Virology & Antivirals  
Sports Medicine And Injury Care Journal | ISSN: 2689-8829  
Trends In Anatomy & Physiology | ISSN: 2640-7752

Submit Your Manuscript: <https://www.heraldoopenaccess.us/submit-manuscript>